Buying Nymox Pharmaceutical Stock in 2026: A Very High-Risk Case
Looking for information on Nymox Pharmaceutical stock? This profile presents the case without embellishment: a very small biotech with no commercial revenue, traded over the counter (OTC) under the ticker NYMXF, with a residual market cap of a few million dollars and a financial history weighed down by losses. Before considering any purchase, read the list of risks: this stock belongs to the most speculative category of investments there is.
Nymox Pharmaceutical Stock Price
The stock trades OTC (the US over-the-counter market) under the ticker NYMXF, not on a major regulated exchange. Its 12-month price range is extreme, with a residual market cap of around $4 million and almost no trading volume: just a few thousand shares traded per day are enough to move the quote sharply. These conditions make order execution unpredictable and exiting a position very uncertain.
Nymox Pharmaceutical Stock Profile
| Company | Nymox Pharmaceutical Corporation |
| Market | OTC (over the counter, United States) — checked on November 10, 2026 |
| Ticker | NYMXF |
| Founded / Headquarters | 1989 · company with a very small workforce (around fifteen people) |
| Sector | Biotechnology: drug candidates in development, smoking diagnostic tests |
| Trading currency | US dollar (USD) |
| Financial year end | December 31 |
| PEA eligibility | No (listed outside EU regulated markets; PEA eligibility excluded) |
About Nymox Pharmaceutical: Business and Background
A niche biotech with no major commercial product
Nymox Pharmaceutical, founded in 1989, develops products for an ageing population. Its main programme, Fexapotide Triflutate (NX-1207), targets the treatment of benign prostatic hyperplasia and low-grade prostate cancers — an injectable product that remained in clinical development for years without obtaining major commercial approval. The company also sells small smoking diagnostic tests (NicAlert, TobacAlert), niche products that do not generate significant revenue.
A deteriorating financial position
The published accounts show annual losses in every financial year, no meaningful revenue and a cash position structurally dependent on capital transactions — which dilute existing shareholders. The extreme discount on its market cap and its OTC listing reflect this situation: the market sees the company’s survival as the first question to settle, ahead of any clinical development scenario.
What this means for an investor
In practical terms: a company with no revenue has to fund its expenses by issuing new shares, which automatically dilutes existing holders; an OTC listing with low volumes makes it hard to buy or sell at the displayed price; and the stock’s history includes episodes where the price was divided by considerable factors. None of these points is an opinion: they are verifiable features of the case as published.
Nymox Results and Financial Data
The accounts for the latest published financial years show a company with no meaningful revenue, posting annual net losses of several million dollars (around $4 million to $9 million in recent years, and more than $12 million in 2021), with no proven break-even point.
Source: StockAnalysis, consolidated accounts; data accessed on November 10, 2026.
We do not present a detailed multi-year table: the series of published figures does not describe a business trajectory — it describes cash burn. That is precisely what should guide the decision: in this type of case, classic growth and margin analysis does not apply.
Diversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →Nymox Pharmaceutical Stock Dividend
Nymox pays no dividend and cannot pay one in its current situation: a company with continuous losses has no profits to distribute.
Any promise of income associated with this stock would be wrong. The only way to make a gain is a rise in the share price, the probability of which cannot be estimated with confidence under the stock’s current market conditions.
Should You Buy Nymox Pharmaceutical Stock in 2026?
Potential positives:
- A long-running clinical programme (NX-1207) that has accumulated years of studies on prostate enlargement.
- Diagnostic tests sold on a small scale (NicAlert, TobacAlert).
- A residual market cap: if a turnaround did happen, the arithmetic would allow for strong gains.
Points to watch — all of them major:
- No significant commercial revenue and persistent annual losses.
- Total dependence on fundraising, which dilutes existing shareholders.
- OTC listing with almost no volume: exiting a position at the displayed price is very uncertain.
- A price history marked by extreme collapses over twelve months.
- No dividend, no analyst coverage, limited transparency.
Our view is unambiguous: this case is not a classic long-term investment. At best, it is a residual speculative position in which a total loss must be considered a likely scenario. No decision should be made without reading the filings submitted by the company itself.
Fundamental and Technical Analysis of NYMXF Stock
Fundamental analysis
The usual indicators (growth, margins, yield) do not apply. The only thing to track is net cash and the funding timeline: until the company demonstrates a source of revenue or a major pharmaceutical partner, every financial year ends with capital being consumed. This is a survival criterion, not a valuation one.
Technical analysis
On an OTC stock with almost no volume, the usual technical patterns have almost no predictive value: a single order can move the price by tens of percent. Our introduction to trading recalls the first rule: never trade an instrument whose liquidity you do not control.
How to Buy Nymox Pharmaceutical Stock
If, after reading the risks, you still want to take a position:
- Choose a broker that gives access to the US OTC market — not all of them do; compare our selection of the best stock brokers.
- Open an ordinary securities account (the stock is not eligible for a PEA) and complete identity verification.
- Research the company: read Nymox’s latest financial filings before placing any order.
- Place a limit order for an amount you are prepared to lose entirely.
Taxation
Capital gains are subject to the 30% flat tax (PFU) in a securities account. In the event of a total loss, French capital loss rules apply according to the regulations in force.
Frequently Asked Questions About Nymox Pharmaceutical Stock
Which exchange is Nymox Pharmaceutical traded on?
OTC (the US over-the-counter market), ticker NYMXF. The stock is not listed on the NYSE or the Nasdaq, which limits the brokers that offer it and its liquidity.
Does Nymox pay a dividend?
No. The company is making continuous losses and has no distributable profit.
Can you hold NYMXF stock in a PEA?
No. The stock is not eligible for the PEA; it could only be held, with multiple constraints, in an ordinary securities account — our PEA guide explains what is allowed in one.
What are Nymox’s results?
No meaningful revenue and annual net losses of several million dollars over the latest published financial years.
Is this stock suitable for a retail investor?
In the vast majority of cases, no: with no revenue, no dividend and almost no liquidity, it does not have the profile of a portfolio investment. Before making any decision, review our method for buying shares and compare it with solid candidates among the best stocks.
Disclaimer: this content is for information only and does not constitute investment advice. Investing in the stock market carries a risk of capital loss; past performance is not a reliable indicator of future performance.
